Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
09 Mayo 2024 - 3:42PM
Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters,
including updated clinical trial data, for vepdegestrant will be
presented at the 2024 European Society for Medical Oncology (ESMO)
Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin,
Germany. Vepdegestrant is a novel investigational PROTAC® estrogen
receptor (ER) degrader that is being jointly developed by Arvinas
and Pfizer for the treatment of patients with early and locally
advanced or metastatic ER positive/human epidermal growth factor
receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Poster session details are as follows:Date:
Thursday, May 16, 2024Time: 12:00 – 1:00 p.m. CET/ 6:00 – 7:00 a.m.
ETCategory: Metastatic Breast Cancer
- Poster Title and Number: Vepdegestrant, a
PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER)
degrader, plus palbociclib (palbo) in ER+/human epidermal growth
factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b
cohort results, Poster 218PPresentation
Type and Abstract Number: Abstract, 453
- Poster Title and Number: TACTIVE-K: phase 1b/2
study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC)
estrogen receptor (ER) degrader, in combination with PF-07220060, a
cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal
growth factor receptor 2 (HER2)- advanced breast cancer,
Poster 264Presentation Type and Abstract
Number: Trial-in-Progress (TiP), 488
Abstracts are now available via the official ESMO Breast Cancer
Annual Congress website here.
About Vepdegestrant Vepdegestrant is an
investigational, orally bioavailable PROTAC protein degrader
designed to specifically target and degrade the estrogen receptor
(ER) for the treatment of patients with ER positive (ER+)/human
epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-)
breast cancer. Vepdegestrant is being developed as a potential
monotherapy and as part of combination therapy across multiple
treatment settings for ER+/HER2- metastatic breast cancer.
In July 2021, Arvinas announced a global collaboration with
Pfizer for the co-development and co-commercialization of
vepdegestrant; Arvinas and Pfizer will share worldwide development
costs, commercialization expenses, and profits.
The U.S. Food and Drug Administration (FDA) has granted
vepdegestrant Fast Track designation as a monotherapy in the
treatment of adults with ER+/HER2- locally advanced or metastatic
breast cancer previously treated with endocrine-based therapy.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has four investigational clinical-stage programs:
vepdegestrant for the treatment of patients with locally advanced
or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide
for the treatment of men with metastatic castration-resistant
prostate cancer; and ARV-102 for the treatment of patients with
neurodegenerative disorders. For more information, visit
www.arvinas.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
plans with respect to vepdegestrant as a potential monotherapy and
combination across multiple treatment settings for ER+/HER2-
metastatic breast cancer. All statements, other than statements of
historical facts, contained in this press release, including
statements regarding Arvinas’ strategy, future operations, future
financial position, future revenues, projected costs, prospects,
plans and objectives of management, are forward-looking statements.
The words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Arvinas may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and you
should not place undue reliance on such forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements Arvinas makes as a result of various risks and
uncertainties, including but not limited to: Arvinas’ and Pfizer,
Inc.’s (“Pfizer”) performance of the respective obligations with
respect to Arvinas’ collaboration with Pfizer; whether Arvinas and
Pfizer will be able to successfully conduct and complete clinical
development for vepdegestrant (ARV-471); whether Arvinas and
Pfizer, as appropriate, will be able to obtain marketing approval
for and commercialize vepdegestrant (ARV-471)on current timelines
or at all; Arvinas’ ability to protect its intellectual property
portfolio; whether Arvinas’ cash and cash equivalent resources will
be sufficient to fund its foreseeable and unforeseeable operating
expenses and capital expenditure requirements; and other important
factors discussed in the “Risk Factors” section of Arvinas’ Annual
Report on Form 10-K for the year ended December 31, 2023 and
subsequent other reports on file with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Arvinas’ current views with respect to
future events, and Arvinas assumes no obligation to update any
forward-looking statements, except as required by applicable law.
These forward-looking statements should not be relied upon as
representing Arvinas’ views as of any date subsequent to the date
of this release.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024